BELLEVILLE, ON, Oct. 18, 2013 /CNW/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has posted on the
Company's website (www.Bioniche.com), on SEDAR www.sedar.com, and on www.ASX.com.au the management proxy circular relating to the Annual and Special
Meeting of Bioniche Life Sciences Inc. Shareholders. The notice of
meeting and management information circular (the "Circular") has been
mailed to all shareholders of record as at September 9, 2013.
The Annual and Special Meeting of Shareholders will be held at 4:00 p.m.
Eastern on November 5, 2013 in the Park Ballroom at the Travelodge
Hotel, 11 Bay Bridge Road, Belleville, Ontario, Canada. All
shareholders are encouraged to vote in person or by proxy. Details
regarding how to vote are contained in the Circular.
The Company has retained Laurel Hill Advisory Group ("Laurel Hill") to
act as proxy solicitation agent and to respond to inquiries from
Bioniche shareholders. Laurel Hill may be contacted by telephone at
1-877-452-7184 toll-free in North America and at 416-304-0211 for
collect calls outside of North America, or by email at email@example.com.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and One
Health. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097